ArticleCurrent issues in molecular biology2026
The Mechanism of Action of Stigmasterol in Bone Formation in Osteoporosis.
Article in Current issues in molecular biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Osteoporosis (OP) is a metabolic bone disease characterized by reduced bone mass and impaired bone microarchitecture, significantly impacting patients' quality of life. Stigmasterol (STG), a natural plant sterol, has been reported to possess multiple biological activities. However, its effects on OP bone formation and underlying molecular mechanisms remain unclear. The effects of STG on OP bone formation and potential mechanisms were investigated through in vivo and in vitro experiments combined with network pharmacology analysis. An OP model was established in ovariectomized (OVX) rats, and the bone-protective effects of STG were evaluated via micro-CT analysis and histological staining. In vitro experiments, MC3T3-E1 pre-osteoblasts were used to assess STG's influence on osteogenic differentiation through Western blot analysis and ALP/ARS staining. Network pharmacology methods were used to predict potential targets and signaling pathways for STG in OP treatment, followed by mechanism validation. STG significantly improved bone microarchitecture in OVX rats, increased key osteogenic marker expression, and promoted MC3T3-E1 osteogenic differentiation in a dose-dependent manner. Network pharmacology analysis predicted 278 potential targets for STG in treating OP, with pathway enrichment analysis indicating significant involvement of the JAK/STAT pathway. Mechanistic studies revealed that STG promotes osteogenic differentiation by activating the JAK2/STAT3 signaling cascade. As an osteogenic promoter, STG effectively alleviates bone loss and enhances osteoblast differentiation by activating the JAK2/STAT3 signaling pathway.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.